Search

Displaying results 4821 - 4830 of 10000 in total
  1. Drug

    PF-06459988

    go.drugbank.com/drugs/DB14768
    Investigational

    PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

  2. Drug

    Ampreloxetine

    go.drugbank.com/drugs/DB15348
    Investigational

    Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

  3. Drug

    ALT-801

    go.drugbank.com/drugs/DB15386
    Investigational

    ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).

  4. Drug

    Alagebrium

    go.drugbank.com/drugs/DB12497
    Investigational

    Alagebrium has been investigated for the treatment and prevention of Aging, Heart Failure, Physical Activity, Diabetic Nephropathy, and Cardiovascular Disease, among others.

  5. Drug

    DAR-0100A

    go.drugbank.com/drugs/DB16139
    Investigational

    DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).

  6. Drug

    Denifanstat

    go.drugbank.com/drugs/DB17576
    Investigational

    Due to its antineoplastic activities, it is being investigated for various cancers.

  7. Drug

    E1v1.11

    go.drugbank.com/drugs/DB18363
    Experimental

    E1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]

  8. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    Orbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

  9. Drug

    Ganetespib

    go.drugbank.com/drugs/DB12047
    Investigational

    Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

  10. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).